Helix BioPharma Grants Stock Options, Cancels Previous Grants

Helix BioPharma Corp., a clinical-stage oncology company listed on TSX (HBP), OTC PINK (HBPCD), and FRANKFURT (HBP0), has announced the grant of 1,297,000 incentive stock options to its directors, officers, employees, and consultants under its equity compensation plan. Each option allows the purchase of one common share at $1.63 per share for five years, subject to vesting provisions. Concurrently, the company cancelled 2,200,000 stock options previously granted to a director on July 19, 2024, which had an exercise price of $1.10 per share and were set to expire in 2029. This director did not receive any new options in the current grant.

Helix BioPharma is focused on developing therapies for hard-to-treat cancers. Its lead candidate, Tumor Defense Breaker™ L-DOS47, is an antibody-enzyme conjugate designed to target CEACAM6-expressing tumors, making them more sensitive to existing treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC). The company is also advancing next-generation bi-specific antibody-drug conjugates (ADCs) based on the same CEACAM6-targeting foundation. Additionally, Helix has two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to IV administration.

The stock option adjustments reflect Helix's ongoing efforts to align incentives with long-term value creation. The company's innovative pipeline, including L-DOS47 and its oral prodrug GEMCEDA, aims to address significant unmet needs in oncology. For more details, visit the original release on NEWMEDIAWIRE.